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Abstract 
 
Background: Tuberculosis (TB) is a major cause of death worldwide. Finding an effective vaccine 
against TB is the best way to control it. Several vaccines against this disease have been developed 
but none are completely protective. The aim of this study was to design and construct a cloning 
vector containing the Mycobacterium tuberculosis (M. tuberculosis) heat shock protein X (hspX). 
Methods: First, an hspX fragment was amplified by PCR and cloned into plasmid pcDNA3.1(+) and 
recombinant vector was confirmed. 
Results: A 435 bp hspX fragment was isolated. The fragment was 100% homologous with hspX of M. 
tuberculosis strain H37Rv in GenBank. 
Conclusions: In this study, the cloning vector pcDNA3.1(+), containing a 435-bp hspX fragment of M. 
tuberculosis, was constructed. This could be used as a DNA vaccine to induce immune responses in 
animal models in future studies. 
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Introduction 
Mycobacterium (M.) tuberculosis was first 
identified as the cause of tuberculosis (TB) by 
Robert Koch in 1882. Tuberculosis (TB), for 
thousands of years, was known as the "human 
plague" (1). Tuberculosis is one of the most 
important infectious diseases and a major cause 
of death worldwide, especially in developing 
countries. One-third of the world's population is 
infected with M. tuberculosis, and every second 
another individual is added to them (2). 
According to the World Health Organization 
(WHO), approximately 7.1 billion people are 
infected with M. tuberculosis and more than 20 
million of those suffer from the disease. More 
than 9 million individuals are infected every 
year, resulting in about 1.5 million deaths. M.
 
tuberculosis infections, with malaria and AIDS, 
are considered to have the highest death rates of 
all infectious diseases (3-6). 
Currently the Bacillus Calmette-Guerin 
(BCG) vaccine is the only TB vaccine in use in 
many countries. Although the BCG vaccine 
protects against TB in children, it is not effective 
against pulmonary TB in adults (6-8) 
Heat shock protein X (hspX) has been purified 
from M. tuberculosis. Heat shock protein X has a 
proposed role in the maintenance of long-term 
viability during latent, asymptomatic infections, and 
in replication during initial infection (9, 10). This 
antigen stimulates CD4+ and CD8+ T cells and 
induces TNF-α, IL-2, and IFN-γ expression (11). 
In the present study, hspX from M. tuberculosis 
D
ow
nl
oa
de
d 
fro
m
 rb
m
b.
ne
t a
t 7
:1
6 
IR
ST
 o
n 
Th
ur
sd
ay
 J
an
ua
ry
 5
th
 2
01
7
Yaghoubi A et al. 
     Rep. Biochem. Mol. Biol, Vol. 5, No. 1, Oct 2016    47 
was cloned into plasmid pcDNA3.1(+). This 
construct could be used as a DNA vaccine to induce 
immune responses in animal models in future studies. 
 
Materials and Methods 
1. PCR amplification of hspX  
In this study, M. tuberculosis strain H37Rv (Pasteur 
institute of Iran) DNA was extracted by boiling as 
described previously (4,12). hspX was amplified by the 
polymerase chain reaction (PCR) using forward 
(5'tatttcggatccaccatggccaccacccttcccgtt3’) and reverse 
(5'attatttctagattatcagttggtggaccggatctgaat3') primers. 
The PCR reaction was prepared and gene 
amplification was performed for 4 min at 95°C, 
followed by 35 cycles at 94°C for 30 sec, 59°C for 30 
sec, and 72°C for 30 sec. The final amplification was 
performed for 10 minutes at 72°C. PCR products were 
analyzed using 1.5% agarose gel and Green viewer 
staining (ParsTous, Iran). 
2. Cloning of hspX into pcDNA3.1(+) 
The amplified hspX fragment and pcDNA3.1(+) 
were digested with BamHI and XbaI (Fermentas, 
Germany) restriction enzymes. Digested products 
were purified with a gel purification kit (Bioneer, 
South Korea) according to the manufacturer’s 
recommendations. For insertion of hspX into 
pcDNA3.1(+), we used ligation solution containing 
14.5 µl of digested and purified pcDNA3.1(+), 8 µl 
of digested and purified hspX DNA, 2.5 µl of T4 
DNA ligase buffer, 0.2 µl of T4 DNA ligase 
(Vivantis, Malaysia), and 2 µl of polyethylene 
glycol (PEG) (Thermo Scientific, USA). The 
mixture was incubated overnight at 16°C as 
described previously (12, 13). Escherichia (E.) coli 
strain TOP10 cells were transformed with this 
construct. Transformants were confirmed by 
colony-PCR using the hspX-specific primers 
described above, restriction enzyme digestion with 
BamHI and XbaI, and sequencing (MacroGen, 
South Korea). 
Results 
In this study, an hspX fragment was amplified 
by PCR from M. tuberculosis H37Rv genomic 
DNA (Figure 1) and cloned into pcDNA3.1 
(+). In colony-PCR a fragment of 435 bp was 
observed (Figure 2). Presence of the 435 bp 
fragment was confirmed by double-digestion 
of the recombinant vector. DNA sequencing 
showed the fragment was 100% homologous 
with hspX of M. tuberculosis strain H37Rv 
recorded in GenBank. 
 
 
 
Fig .1. Agarose Gel Electrophoresis of hspX PCR Product. Lane 1: 
435 bp hspX PCR product; lane M: 1 kb DNA size marker 
 
 
 
 
 
 
Fig .2. Colony-PCR results using hspX-specific primers. Lane 1: 
PCR product of hspX, Lane M: 1 kb DNA size marker 
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Discussion 
Tuberculosis is caused by infection with M. 
tuberculosis and a major cause of death worldwide. 
Currently, almost a third of the world’s population is 
asymptomatically infected with M. tuberculosis 
(14,15). The increased prevalence of TB depends on 
three main factors: the AIDS pandemic, the 
emergence of multidrug-resistant TB strains, and the 
failure of vaccination programs (6, 16). 
Although BCG as a vaccine against TB was 
approved, it cannot prevent latent TB infections. To 
control this disease it will be necessary to design a 
vaccine that can enhance immunogenicity (6, 12). 
Recently, many studies have attempted to produce 
effective vaccines against TB. These vaccines 
include viral vectors, DNA vaccines, subunit 
vaccines with fusion proteins, and recombinant 
BCG (9, 17, 18).  
DNA vaccines can stimulate both humoral and 
cellular immunity. This property can be useful to 
prevent infections caused by intracellular pathogens, 
such as M. tuberculosis (4, 19). Several antigens, 
including Ag85B, TB10.4, AG85BAg85B, ESAT-
6, MPB83, MPB32, and hspX HSPX are TB 
vaccine candidates (20, 21). 
Shi et al. studied T cell responses against the M. 
tuberculosis Ag85B and hspX gene products and 
suggested that latency antigens of M. tuberculosis 
may be promising targets for developing more 
effective recombinant BCG strains than are 
presently available to protect against TB (22). 
In an effort by Niu et al. to find an effective 
vaccine to increase the immunogenicity and 
protective efficacy of BCG, and control or eliminate 
M. tuberculosis in all stages of infection, antigens of 
MTB10.4, expressed in replicating bacilli, and hspX, 
expressed in dormant bacilli, were fused to produce 
a subunit vaccine. IFN-γ and IL-17 expression was 
greater in spleen lymphocytes of mice vaccinated 
with the subunit vaccine than in those of the control 
group, who were vaccinated with BCG. These 
findings suggest that HSPX-MTB10.4 has the 
potential to be a good multistage TB vaccine 
candidate (23). 
Taylor et al. demonstrated that HSPX has the 
potential to elicit both short- and long-term 
protective effects. Recent studies have shown that 
IFN-γ production in cells from mice vaccinated with 
HSPX is significantly greater than that of mice
 
vaccinated with BCG. The ability of HSPX to 
stimulate CD4+ T cells was also evaluated. For this 
purpose, spleen cells from mice were examined six 
months after the vaccination. The number of CD4+ 
T cells and abundance of cytokines TNF-α, IL-2, 
and IFN-γ in the cells of mice vaccinated with hspX 
were greater than those of mice vaccinated with 
BCG. Thus, HSPX may be a good TB vaccine 
candidate (11). 
Haldar et al. analyzed GlcB and hspX DNA and 
proteins for early detection and treatment of 
tuberculosis meningitis (TBM) in children. 
Cerebral spinal fluid samples from 555 TBM-
positive children (M. tuberculosis-culture positive, 
n = 29) were collected from three centers in Delhi. 
In this test, TBM (true positives) and NTIM (true 
negative) groups were defined and samples from 
both groups were analyzed by PCR and ELISA and 
compared for sensitivity. The ELISA showed 100% 
sensitivity and 96-97% specificity in the TBM 
samples. This study showed that GlcD and hspX 
can be appropriate targets for early diagnosis of 
TBM and accelerating the detection process (24). 
In another effort to develop an effective DNA 
vaccine against M. tuberculosis, the mycobacterial 
genes, Rv3407, Ag85A, and hspX were joined in a 
single open reading frame by 2A sequences and the 
resulting recombinant subunit vaccine was called 
V-2A. V-2A injected into mice elicited both 
cellular and humoral immune responses against all 
three antigens. This vaccine also protected the mice 
against M. tuberculosis aerosol challenge. This 
result can help in the design and development of 
efficacious recombinant subunit vaccines in future 
studies (25). 
In this study, hspX of M. tuberculosis H37Rv was 
amplified by PCR and cloned into pcDNA3.1(+). 
The construct may be used as a DNA vaccine to 
induce immune system responses in animal models 
in future studies. 
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